- Home
- SRZN vs LUCD Comparison
SRZN vs LUCD Comparison
Compare SRZN & LUCD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SRZN | LUCD |
|---|---|---|
| Founded | 2015 | 2018 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 117.8M | 132.4M |
| IPO Year | N/A | 2021 |
Fundamental Metrics
Financial Performance| Metric | SRZN | LUCD |
|---|---|---|
| Price | $21.72 | $1.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $38.50 | $3.94 |
| AVG Volume (30 Days) | 107.8K | ★ 720.5K |
| Earning Date | 11-07-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $3,604,000.00 | ★ $4,399,000.00 |
| Revenue This Year | N/A | $12.31 |
| Revenue Next Year | N/A | $152.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 5.01 |
| 52 Week Low | $5.90 | $0.75 |
| 52 Week High | $24.94 | $1.80 |
Technical Indicators
Market Signals| Indicator | SRZN | LUCD |
|---|---|---|
| Relative Strength Index (RSI) | 66.16 | 52.35 |
| Support Level | $14.94 | $1.02 |
| Resistance Level | $24.94 | $1.16 |
| Average True Range (ATR) | 1.84 | 0.05 |
| MACD | 0.67 | 0.01 |
| Stochastic Oscillator | 72.57 | 66.24 |
Price Performance
Historical ComparisonAbout SRZN Surrozen Inc.
Surrozen Inc is a clinical-stage biotechnology company committed to discovering and developing drug candidates to selectively modulate the Wnt pathway, a critical mediator of tissue repair, in a broad range of organs and tissues. Its product candidate includes SZN-1326 (Fzd5/Lrp6, SWAP), SZN-413 and SZN-043 (E3/ASGR1, SWEETS).
About LUCD Lucid Diagnostics Inc.
Lucid Diagnostics Inc is a commercial-stage medical diagnostics technology company focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, acid reflux, or simply reflux, who are at risk of developing esophageal precancer and cancer, specifically lethal esophageal adenocarcinoma. Its products include EsoCheck and EsoGuard.